<DOC>
	<DOCNO>NCT03037931</DOCNO>
	<brief_summary>The primary objective study determine efficacy safety iron therapy use intravenous ( IV ) ferric carboxymaltose ( FCM ) , relative placebo , treatment participant heart failure iron deficiency reduce ejection fraction .</brief_summary>
	<brief_title>Randomized Placebo-controlled Trial FCM Treatment Heart Failure With Iron Deficiency</brief_title>
	<detailed_description>This double-blind , multicenter , prospective , randomize , placebo-controlled study ass effect IV FCM compare placebo 12-month rate death , hospitalization worsen heart failure , 6-month change 6 minute walk test ( 6MWT ) patient heart failure iron deficiency . After initial screening period 28 day , eligible participant stratified region randomize 1:1 ratio FCM placebo treatment . Study drug administration occur Day 0 Day 7 ( ±2 ) undiluted slow IV push , additional study visit plan 3 month interval , additional dosing administer every 6 month applicable . In subset site , participant return recurrent laboratory assessment ( chemistry , hematology iron index ) Day 21 ( ± 7 ) course investigational treatment . For participant , hematology , ferritin , transferrin saturation ( TSAT ) , appropriate safety evaluation , determine additional treatment , occur 6 month interval .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Adult ( ≥18 year age ) able provide inform consent . 2 . Stable heart failure ( NYHA IIIV ) maximallytolerated background therapy ( determine site Principle Investigator ) least 4 week dose change heart failure drug last 2 week . 3 . Able willing perform 6MWT time randomization . 4 . Reduced leave ventricular ejection fraction . Assessment must perform least 12 week major cardiac surgical intervention include coronary artery bypass graft ( CABG ) , valvular repair/replacement , cardiac resynchronization therapy ( CRT ) device implantation . . Left ventricular ejection fraction ≤35 % obtain screening visit OR either follow . Historical value ejection fraction ≤35 % within 12 month screen visit ii . Historical value ejection fraction ≤25 % within 24 month screen visit 5 . Hemoglobin &gt; 9.0 g/dL &lt; 13.5 g/dL ( female ) &lt; 15.0 g/dL ( male ) . 6 . Serum ferritin &lt; 100 ng/mL 100 300 ng/mL TSAT &lt; 20 % . 7 . Either documented hospitalization heart failure within 12 month enrollment screen visit Nterminalprobrain natriuretic peptide ( NTproBNP ) &gt; 600 pg/ml ( BNP &gt; 200 pg/mL ) patient normal sinus rhythm NTproBNP &gt; 1000 pg/ml ( BNP &gt; 400 pg/mL ) patient atrial fibrillation . NOTE : NTproBNP must use confirm eligibility patient take sacubitril/valsartan . 1 . Current planned oral iron supplementation . Ironcontaining multivitamin ( &lt; 30 mg /day ) permit . 2 . Known hypersensitivity reaction component FCM . 3 . History acquire iron overload , recent receipt ( within 3 month ) erythropoietin stimulate agent , IV iron therapy , blood transfusion . 4 . Acute myocardial infarction , acute coronary syndrome , transient ischemic attack , stroke within 3 month enrollment . 5 . Uncorrected severe aortic stenosis , severe valvular regurgitation , leave ventricular outflow obstruction require intervention . 6 . Current atrial fibrillation atrial flutter mean ventricular response rate &gt; 100 per minute ( rest ) . 7 . Current plan mechanical circulatory support heart transplantation . 8 . Hemodialysis peritoneal dialysis ( current plan within next 6 month ) . 9 . Documented liver disease , active hepatitis ( i.e . alanine transaminase aspartate transaminase &gt; 3 time upper limit normal range ) . 10 . Current recent ( within 3 year ) malignancy exception basal cell carcinoma squamous cell carcinoma skin , cervical intraepithelial neoplasia . 11 . Known gastrointestinal bleeding . Patients screen ferritin &lt; 15ng/ml must appropriate evaluation within 3 month screen . 12 . Female participant childbearing potential pregnant , lactating , willing use adequate contraceptive precaution study 5 day last scheduled dose study medication . 13 . Inability return follow visit within necessary window</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>